BioNTech Faces Courtroom Grind and Factory Closures as Founders Chart a Separate Path

BioNTech will shut three German production sites by end-2028, affecting up to 1,860 jobs, as a Delaware court keeps Bayer's patent suit alive.

A Delaware federal court has refused to throw out Bayer's patent suit against Pfizer and BioNTech, clearing the way for a full hearing on allegations that the partners infringed mRNA technology used in COVID-19 vaccines. Monday's ruling made no finding of infringement — but it keeps a potentially costly case alive at the very moment BioNTech is trying to reinvent itself as an oncology specialist.

The legal front is only one of several pressure points converging on the Mainz-based biotech. BioNTech confirmed on Monday that it will shut three German production sites after failing to find buyers, a retreat that stretches from the end of 2027 through the end of 2028. Tübingen is slated to close at the end of 2027, Marburg at the start of 2028, and Idar-Oberstein at the end of 2028. Reuters puts the total number of jobs affected across the three locations at as many as 1,860.

Trust Erodes at Idar-Oberstein

Employee representatives are pushing back hard. At Idar-Oberstein, where roughly 440 people work, works council chief Jacob Kaufmann described a serious breach of trust on Wednesday, saying the failed sales process and the looming wind-down had permanently damaged the workforce's confidence in management. The company, according to a Handelsblatt report, blamed the collapse of sale talks on a difficult market and investment environment.

The closures amount to an official admission of overcapacity left over from the vaccine boom. Optimists read the retreat from Marburg, Tübingen and Idar-Oberstein as a necessary cleanup that ends expensive idle capacity and frees capital for later-stage clinical trials. Critics see a drawn-out restructuring — one whose closure deadlines run to the end of 2028 — that risks disrupting day-to-day operations while the revenue base from COVID-19 continues to shrink.

Sahin Keeps Selling Under a Pre-Set Plan

Meanwhile, CEO U?ur ?ahin continues to trim his stake. Mandatory filings with the U.S. Securities and Exchange Commission show he sold 32,000 ordinary shares on Wednesday, following a package of 34,000 shares on Monday. Both tranches were executed under a trading plan established on 3 June 2026 and governed by U.S. Rule 10b5-1, a mechanism that automates sales according to pre-defined criteria. The timing, however, coincides with a period of internal upheaval.

Adding to the debate is the future role of the company's scientific founders. Handelsblatt reported on 24 September on friction surrounding plans by ?ahin and Özlem Türeci to build a new venture called Arife SE, headquartered in Mainz. Questions over patents, financing and personnel are said to be in play as the separation unfolds. The founders intend to remain BioNTech shareholders, and Arife SE is not a subsidiary of the company — a distinction that nonetheless sharpens investors' appetite for clarity on where strategic priorities will sit.

Oncology Data Provide the Counterweight

Against the noise, the operating story away from the old plants has offered reasons for confidence. Updated Phase 3 data on the antibody candidate Gotistobart delivered fresh momentum about two weeks ago, lifting the stock 2.9% since. Berenberg analysts raised their price target around the same time, a call accompanied by a 3.0% share gain. Progress in oncology, the bulls argue, shows the platform still generates viable product candidates.

The central question for any investment case is now straightforward: can BioNTech complete the transition from pandemic-era windfall to profitable oncology specialist in time? A protracted Bayer case could tie up significant resources. Should the company rebut Bayer's claims, a substantial valuation discount would fall away; should Bayer prevail, BioNTech and Pfizer face the prospect of retroactive compensation or future licensing fees, and the Delaware decision raises the odds of a lengthy trial.

Chart Levels Frame the Next Move

The shares trade at EUR 86.10, just above their 200-day moving average of EUR 84.58. Hold that level and the broader recovery scenario stays intact; a sustained break below it opens the door to a retest of lower support. The paper remains well short of its 52-week high of EUR 105.80.

In today's session the stock added 0.4% to EUR 86.50, giving BioNTech a market value of EUR 21.59 billion. Investors are weighing how far the manufacturing overhaul will reshape the cost base and operating capacity. The next concrete catalyst is the course of the Delaware patent proceedings, alongside fresh trial readouts from the cancer pipeline — new data on candidates such as Gotistobart will decide whether the fundamental realignment outweighs the operational legacy of the vaccine years.